Skip to main content

PTLD Up for Seronegative Recipients of Epstein-Barr Virus-Seropositive Donor Kidneys

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 5, 2025.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, Feb. 5, 2025 -- Epstein-Barr virus (EBV)-seronegative recipients of EBV-seropositive donor (EBV D+/R−) kidneys have an increased risk for posttransplant lymphoproliferative disorder (PTLD), according to a study published online Jan. 28 in the Annals of Internal Medicine.

Vishnu S. Potluri, M.D., M.P.H., from the Hospital of the University of Pennsylvania, and colleagues conducted a retrospective cohort study to examine the associations between pretransplant EBV D+/R− and recipient EBV-seropositive status (R+) and the outcomes of PTLD and graft and patient survival in adult recipients of kidney transplant.

The final cohort included 104 EBV D+/R− recipients matched to 312 EBV R+ recipients. The researchers found that 50 (48.1 percent) of the EBV D+/R− recipients developed EBV DNAemia, with a median time of 198 days after transplant. At a median of 202 days after transplant, 23 (22.1 percent) EBV D+/R− recipients had PTLD. Higher all-cause graft failure was seen in EBV D+/R− recipients (hazard ratio, 2.21; 95 percent confidence interval, 1.06 to 4.63), and mortality was higher but the increase was not statistically significant (hazard ratio, 2.19; 95 percent confidence interval, 0.94 to 5.13).

"Our findings highlight the need for strategies to attenuate the effect of donor-derived EBV infection among EBV-seronegative recipients and for counseling prospective EBV D+/R− recipients about the elevated risk for early PTLD," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted February 2025

Read this next

GLP-1 RA Use Tied to Better Kidney Transplant Outcomes in Patients With Diabetes

TUESDAY, March 18, 2025 -- Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with better graft and patient survival among kidney transplant recipients with...

Seroprevalence of HPAI A(H5) Identified in Bovine Veterinary Practitioners

FRIDAY, Feb. 14, 2025 -- Seroprevalence of highly pathogenic avian influenza (HPAI) A(H5) virus infection has been identified among bovine veterinary practitioners, according to...

COVID-19 Linked to More Severe Outcomes Than Flu, RSV in 2022-2023 Season

THURSDAY, Jan. 30, 2025 -- COVID-19 was associated with more severe disease outcomes than influenza or respiratory syncytial virus (RSV) during the 2022 to 2023 season, according...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.